191 related articles for article (PubMed ID: 14656474)
21. Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.
Wallen JW; Cate RL; Kiefer DM; Riemen MW; Martinez D; Hoffman RM; Donahoe PK; Von Hoff DD; Pepinsky B; Oliff A
Cancer Res; 1989 Apr; 49(8):2005-11. PubMed ID: 2702642
[TBL] [Abstract][Full Text] [Related]
22. Anti-Müllerian hormone and its receptors.
Josso N; di Clemente N; Gouédard L
Mol Cell Endocrinol; 2001 Jun; 179(1-2):25-32. PubMed ID: 11420127
[TBL] [Abstract][Full Text] [Related]
23. Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway.
Segev DL; Ha TU; Tran TT; Kenneally M; Harkin P; Jung M; MacLaughlin DT; Donahoe PK; Maheswaran S
J Biol Chem; 2000 Sep; 275(37):28371-9. PubMed ID: 10874041
[TBL] [Abstract][Full Text] [Related]
24. Müllerian inhibitory substance induces growth of rat preantral ovarian follicles.
McGee EA; Smith R; Spears N; Nachtigal MW; Ingraham H; Hsueh AJ
Biol Reprod; 2001 Jan; 64(1):293-8. PubMed ID: 11133686
[TBL] [Abstract][Full Text] [Related]
25. Cleavage of Müllerian inhibiting substance activates antiproliferative effects in vivo.
Kurian MS; de la Cuesta RS; Waneck GL; MacLaughlin DT; Manganaro TF; Donahoe PK
Clin Cancer Res; 1995 Mar; 1(3):343-9. PubMed ID: 9815990
[TBL] [Abstract][Full Text] [Related]
26. Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance.
Renaud EJ; MacLaughlin DT; Oliva E; Rueda BR; Donahoe PK
Proc Natl Acad Sci U S A; 2005 Jan; 102(1):111-6. PubMed ID: 15618407
[TBL] [Abstract][Full Text] [Related]
27. Autocrine and paracrine Müllerian inhibiting substance hormone signaling in reproduction.
Ingraham HA; Hirokawa Y; Roberts LM; Mellon SH; McGee E; Nachtigal MW; Visser JA
Recent Prog Horm Res; 2000; 55():53-67; discussion 67-8. PubMed ID: 11036933
[TBL] [Abstract][Full Text] [Related]
28. Müllerian-inhibiting substance regulates androgen synthesis at the transcriptional level.
Teixeira J; Fynn-Thompson E; Payne AH; Donahoe PK
Endocrinology; 1999 Oct; 140(10):4732-8. PubMed ID: 10499532
[TBL] [Abstract][Full Text] [Related]
29. Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism.
Ha TU; Segev DL; Barbie D; Masiakos PT; Tran TT; Dombkowski D; Glander M; Clarke TR; Lorenzo HK; Donahoe PK; Maheswaran S
J Biol Chem; 2000 Nov; 275(47):37101-9. PubMed ID: 10958795
[TBL] [Abstract][Full Text] [Related]
30. Human müllerian inhibiting substance inhibits tumor growth in vitro and in vivo.
Chin TW; Parry RL; Donahoe PK
Cancer Res; 1991 Apr; 51(8):2101-6. PubMed ID: 2009529
[TBL] [Abstract][Full Text] [Related]
31. Highly purified müllerian inhibiting substance inhibits human ovarian cancer in vivo.
Stephen AE; Pearsall LA; Christian BP; Donahoe PK; Vacanti JP; MacLaughlin DT
Clin Cancer Res; 2002 Aug; 8(8):2640-6. PubMed ID: 12171896
[TBL] [Abstract][Full Text] [Related]
32. Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.
Barbie TU; Barbie DA; MacLaughlin DT; Maheswaran S; Donahoe PK
Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15601-6. PubMed ID: 14671316
[TBL] [Abstract][Full Text] [Related]
33. The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia.
Song JY; Chen KY; Kim SY; Kim MR; Ryu KS; Cha JH; Kang CS; MacLaughlin DT; Kim JH
Int J Oncol; 2009 Jun; 34(6):1583-91. PubMed ID: 19424576
[TBL] [Abstract][Full Text] [Related]
34. YWK-II protein as a novel G(o)-coupled receptor for Müllerian inhibiting substance in cell survival.
Yin X; Ouyang S; Xu W; Zhang X; Fok KL; Wong HY; Zhang J; Qiu X; Miao S; Chan HC; Wang L
J Cell Sci; 2007 May; 120(Pt 9):1521-8. PubMed ID: 17452623
[TBL] [Abstract][Full Text] [Related]
35. Anti-Proliferative and Apoptotic Activities of Müllerian Inhibiting Substance Combined with Calcitriol in Ovarian Cancer Cell Lines.
Jung YS; Kim HJ; Seo SK; Choi YS; Nam EJ; Kim S; Kim SW; Han HD; Kim JW; Kim YT
Yonsei Med J; 2016 Jan; 57(1):33-40. PubMed ID: 26632380
[TBL] [Abstract][Full Text] [Related]
36. Genetic studies of MIS signalling in sexual development.
Jamin SP; Arango NA; Mishina Y; Behringer RR
Novartis Found Symp; 2002; 244():157-64; discussion 164-8, 203-6, 253-7. PubMed ID: 11990789
[TBL] [Abstract][Full Text] [Related]
37. Mullerian inhibiting substance regulates androgen-induced gene expression and growth in prostate cancer cells through a nuclear factor-kappaB-dependent Smad-independent mechanism.
Tran TT; Segev DL; Gupta V; Kawakubo H; Yeo G; Donahoe PK; Maheswaran S
Mol Endocrinol; 2006 Oct; 20(10):2382-91. PubMed ID: 16740653
[TBL] [Abstract][Full Text] [Related]
38. Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.
Segev DL; Hoshiya Y; Hoshiya M; Tran TT; Carey JL; Stephen AE; MacLaughlin DT; Donahoe PK; Maheswaran S
Proc Natl Acad Sci U S A; 2002 Jan; 99(1):239-44. PubMed ID: 11773638
[TBL] [Abstract][Full Text] [Related]
39. Transduction pathway of anti-Müllerian hormone, a sex-specific member of the TGF-beta family.
Josso N; Clemente Nd
Trends Endocrinol Metab; 2003 Mar; 14(2):91-7. PubMed ID: 12591180
[TBL] [Abstract][Full Text] [Related]
40. Mullerian duct regression and antiproliferative bioactivities of mullerian inhibiting substance reside in its carboxy-terminal domain.
MacLaughlin DT; Hudson PL; Graciano AL; Kenneally MK; Ragin RC; Manganaro TF; Donahoe PK
Endocrinology; 1992 Jul; 131(1):291-6. PubMed ID: 1612008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
